X4 Pharmaceuticals, Inc
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) is a biopharmaceutical company focused on developing and commercializing novel therapeutics for rare hematology diseases. The company's website is www.x4pharma.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What X4 Pharmaceuticals, Inc does
In the company’s own words
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) is a biopharmaceutical company focused on developing and commercializing novel therapeutics for rare hematology diseases. The company's website is www.x4pharma.com.
X4 Pharmaceuticals' primary asset is mavorixafor, a small molecule oral therapeutic that functions as a selective antagonist of the chemokine receptor CXCR4. The company has one FDA-approved product, XOLREMDI (mavorixafor), which received accelerated approval for use in patients 12 years and older with WHIM syndrome, a rare combined primary immunodeficiency and chronic neutropenic disorder. XOLREMDI is indicated to increase the number of circulating mature neutrophils and lymphocytes in these patients. Additionally, the European Medicines Agency's Committee for Medicinal Products for Human Use recommended marketing authorization for mavorixafor in the European Union, with a final approval decision anticipated in the second quarter of 2026.
The company is advancing mavorixafor through a pivotal Phase 3 clinical trial called 4WARD, which evaluates the drug's efficacy and safety in patients with chronic neutropenia who experience recurrent or serious infections. The 52-week trial aims to enroll up to 176 patients, with full enrollment targeted for the third quarter of 2026 and top-line data expected in the second half of 2027. The FDA has granted Fast Track designation to mavorixafor for chronic neutropenia treatment.
X4 Pharmaceuticals has established strategic partnerships to expand its commercial reach. The company entered into a license and supply agreement with Norgine Pharma UK Ltd. granting exclusive rights to commercialize mavorixafor in Europe, Australia, and New Zealand. Additional agreements exist with taiba rare for select Middle East and North African countries and with Abbisko Therapeutics for mainland China, Taiwan, Hong Kong, and Macau.
The company operates under a capital-efficient model utilizing third-party contractors for manufacturing and distribution. During 2025, X4 Pharmaceuticals completed two significant capital-raising transactions, securing approximately $226.6 million in net proceeds to fund operations and support the advancement of its clinical development programs and commercialization efforts.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- BOSTON, MA
- Fiscal year end
- December
- CIK
- 1501697
- SIC
- 2836
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns X4 Pharmaceuticals, Inc — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · X4 Pharmaceuticals, Inc’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do X4 Pharmaceuticals, Inc and its peers compare on margins and cash generation over ten years?”
- “Where did five years of X4 Pharmaceuticals, Inc's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in X4 Pharmaceuticals, Inc's last four quarterly filings that the numbers alone won't show?”